Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndromeOnce-weekly injectable MC4R
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system,
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders
Advancing differentiated MC4R-based obesity programs into clinical developmentMelanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi
Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading
Melanocortin-based therapies
Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN"
PRINCETON, N.J., Nov. 12, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN)
Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in preclinical modelsClinical data supports co-administration of an MC4R agonist with tirzepatide as a safe, potentially
PRINCETON, N.J., Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB:PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50. The Reverse Stock Split
Significant Progress in Obesity and Ocular Programs
Teleconference and Webcast to be held today - May 14, 2025, at 11:00 AM ESTCRANBURY, N.J., May 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT), a
Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection
PL9654 and PL9655 down-regulate inflammatory pathways,
Company Transitioned onto the OTC Pink
CRANBURY, N.J., May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC:PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class
The Company Intends to Request a Review of the Delisting Determination
CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company
Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives
Advancement of novel next-generation MC4R long-acting peptides and oral small moleculesIND applications planned for Q4 2025;
$11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants
CRANBURY, N.J., May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) ("Palatin"
